Abstract:Background: Neuromyelitis optica spectrum disorder (NMOSD) is a rare relapsing autoimmune disease of the central nervous system, affecting mainly optic nerves and spinal cord. NMOSD pathophysiology is associated with anti-aquaporin-4 (AQP4) immunoglobulin G (IgG) autoantibodies. Rapid extracorporeal elimination of autoantibodies with apheresis techniques, such as immunoadsorption (IA), was proven to be an effective treatment of NMOSD attacks. Data on the long-term use of IA to prevent attacks or progression of NMOSD are lacking. Objectives: The aim of this study was to evaluate efficacy and safety of maintenance IA for preventing recurrence of NMOSD attacks in patients refractory to other immunotherapies. Design: Case study. Methods: Retrospective analysis of two female patients with severe NMOSD refractory to conventional immunotherapies was performed. Both patients had responded to tryptophan IA (Tr-IA) as attack therapy and subsequently were treated with biweekly maintenance Tr-IA. Results: Patient 1 (AQP4-IgG seropositive, age 42 years) had 1.38 attacks of optic neuritis per year within 10.1 years before commencing regular Tr-IA. With maintenance Tr-IA for 3.1 years, one mild attack occurred, which was responsive to steroid pulse therapy. Expanded Disability Status Scale (EDSS) was stable at 5.0. Visual function score of the last eye improved from 3 to 1. Patient 2 (AQP4-IgG seronegative, age 43 years) experienced 1.7 attacks per year, mainly acute myelitis and optic neuritis, during the period of 10.0 years before the start of Tr-IA. During regular Tr-IA treatment, no further NMOSD attack occurred. The patient was clinically stable without any additional immunosuppressive treatment for 5.3 years. EDSS improved from 6.0 to 5.0, and the ambulation score from 7 to 1. Tolerability of Tr-IA was good in both patients. No serious adverse events occurred during long-term clinical trajectories. Conclusion: Tr-IA was well tolerated as maintenance treatment and resulted in clinical stabilization of two patients with highly active NMOSD, who were refractory to standard drug therapy.

Hematopoietic stem cell transplantation for neuromyelitis optica spectrum disorder. Can immune tolerance be reestablished?

Treatment of neuromyelitis optica: state-of-the-art and emerging therapies

Moving towards a new era for the treatment of neuromyelitis optica spectrum disorders

Progress in treatment of neuromyelitis optica spectrum disorders (NMOSD): Novel insights into therapeutic possibilities in NMOSD

[Treatment and clinical management of patients with neuromyelitis optica and anti-aquaporin 4 antibody]

Rituximab Therapy for Double Seronegative Neuromyelitis Optica Spectrum Disease

Monoclonal Antibody-Based Treatments for Neuromyelitis Optica Spectrum Disorders: from Bench to Bedside

Advances in disease-modifying therapy of neuromyelitis optica spectrum disorders

Risk of Relapse in Patients with Neuromyelitis Optica Spectrum Disorder: Recognition and Preventive Strategy

Pharmacotherapy for Neuromyelitis Optica Spectrum Disorders: Current Management and Future Options

Brain and spinal cord atrophy in NMOSD and MOGAD: Current evidence and future perspectives

Human Umbilical Cord Mesenchymal Stem Cell Therapy on Neuromyelitis Optica.

Study of the Cytological Features of Bone Marrow Mesenchymal Stem Cells from Patients with Neuromyelitis Optica

Impact of Autologous Mesenchymal Stem Cell Infusion on Neuromyelitis Optica Spectrum Disorder: A Pilot, 2‐year Observational Study

Immunoadsorption as maintenance therapy for refractory neuromyelitis optica spectrum disorder

Application progress of disease modifying drugs in neuromyelitis optica spectrum disorder

Disease-modifying treatments for neuromyelitis optica spectrum disorder in the context of a new generation of biotherapies

Monoclonal Antibody Treatment for Relapse Prevention in Neuromyelitis Optica Spectrum Disorder

Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD) – revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: Diagnosis and differential diagnosis

Autologous hematopoietic stem cell transplantation for pediatric autoimmune neurologic disorders

The current situation of diagnosis and treatment of neuromyelitis optica spectrum disorder: Experience with 461 cases from a single centre in South China